Table 2.
Creatinine and change in estimated GFR during gender-affirming hormone treatment
| Baseline | 6 months | 12 months | 18 months | 24 months | |
|---|---|---|---|---|---|
| Designated male at birth treated with estradiol (n = 92) | |||||
| n | 75 | 54 | 51 | 35 | 29 |
| Serum Creatinine, mean ± SD, mg/dL | 0.83 ± 0.12 | 0.76 ± 0.12* | 0.74 ± 0.11 | 0.75 ± 0.11 | 0.75 ± 0.12 |
| Male SCr/Q, mean ± SD | 1.04 ± 0.15 | 0.93 ± 0.15* | 0.90 ± 0.14 | 0.90 ± 0.14 | 0.89 ± 0.13 |
| Female SCr/Q, mean ± SD | 1.24 ± 0.17 | 1.12 ± 0.18* | 1.09 ± 0.16 | 1.10 ± 0.16 | 1.10 ± 0.16 |
| Baseline | Change from baseline | Change from 6 months | Change from 12 months | Change from 18 months | |
| Male CKiDU25, median (IQR), mL/min/1.73 m2 | 104.3 (93.9, 113.5) | 10.3 (2.2,22.9) | 2.3 (−6.3, 9.1) | 0.7 (−6.8, 11.8) | 3.9 (−12.3,8.7) |
| Female CKiDU25, median (IQR), mL/min/1.73 m2 | 85.5 (77.7,93.9) | 7.6 (1.8,18.0) | 1.9 (−7.0, 7.4) | 0.3 (−5.6,9.6) | 1.1 (−10.0,7.1) |
| Male CKD-EPI 2021, median (IQR), mL/min/1.73 m2 | 131.2 (126.4,134.1) | 2.7 (−0.4,6.9) | −0.1 (−2.8,2.4) | −0.4 (−2.5,3.4) | −0.4 (−3.9,2.4) |
| Female CKD-EPI 2021, median (IQR), mL/min/1.73 m2 | 107.2 (94.9,117.3) | 6.6 (−0.3,12.6) | −0.1 (−4.3,5.8) | −0.4 (−3.3,4.4) | −0.3 (−5.1,5.3) |
| Designated female at birth treated with testosterone (n = 194) | |||||
| n | 150 | 116 | 93 | 77 | 83 |
| Serum Creatinine, mean ± SD, mg/dL | 0.68 ± 0.10 | 0.79 ± 0.11* | 0.82 ± 0.12† | 0.81 ± 0.12 | 0.82 ± 0.14 |
| Male SCr/Q, mean ± SD | 0.88 ± 0.14 | 1.00 ± 0.16* | 1.03 ± 0.14 | 0.99 ± 0.15 | 1.00 ± 0.17 |
| Female SCr/Q, mean ± SD | 1.04 ± 0.16 | 1.20 ± 0.18* | 1.24 ± 0.16 | 1.20 ± 0.18 | 1.21 ± 0.20 |
| Baseline | Change from baseline | Change from 6 months | Change from 12 months | Change from 18 months | |
| Male CKiDU25, median (IQR), mL/min/1.73 m2 | 113.5 (102.8,126.3) | −13.5 (−22.4,−7.2) | −2.2 (−7.3,4.8) | 2.9 (−5.1,8.5) | 0.2 (−8.2,8.1) |
| Female CKiDU25, median (IQR), mL/min/1.73 m2 | 96.0 (87.0,106.9) | −12.4 (−19.7,−6.5) | −2.4 (−6.1,3.4) | 1.9 (−5.2,6.5) | −1.4 (−6.7,6.2) |
| Male CKD-EPI 2021, median (IQR), mL/min/1.73 m2 | 139.8 (135.1,144.8) | −7.1 (−10.3,−3.8) | −2.0 (−6.0,0.8) | 0.1 (−4.3,3.9) | −1.9 (−5.9,2.5) |
| Female CKD-EPI 2021, median (IQR), mL/min/1.73 m2 | 130.9 (121.1,134.7) | −12.2 (−22.9,−5.4) | −3.3 (−9.9,2.9) | 1.2 (−6.6,8.3) | −3.5 (−9.5,6.7) |
*
p< 0.05 for change from baseline measurement
†
p <0.05 for change from 6-month measurement
p values were calculated utilizing a mixed-effects model with age and race as covariates